Therapeutic Advances in Musculoskeletal Disease

Papers
(The TQCC of Therapeutic Advances in Musculoskeletal Disease is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge60
Pathophysiology of musculoskeletal pain: a narrative review45
Osteoporosis in 10 years time: a glimpse into the future of osteoporosis34
Psoriatic arthritis and the association with cardiometabolic disease: a narrative review34
Promising targets for therapy of osteoarthritis: a review on the Wnt and TGF-β signalling pathways33
Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders33
Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of32
Opportunistic diagnosis of osteoporosis, fragile bone strength and vertebral fractures from routine CT scans; a review of approved technology systems and pathways to implementation26
A warning machine learning algorithm for early knee osteoarthritis structural progressor patient screening25
Moving toward targeting the right phenotype with the right platelet-rich plasma (PRP) formulation for knee osteoarthritis24
Body composition in patients with rheumatoid arthritis: a narrative literature review24
Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review20
Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus20
Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)20
A broad look into the future of rheumatoid arthritis19
Large-vessel involvement is predictive of multiple relapses in giant cell arteritis19
Comparative effectiveness of treatment options for subacromial shoulder conditions: a systematic review and network meta-analysis19
Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?19
Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders19
Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies18
Non-steroidal anti-inflammatory drugs in the pharmacological management of osteoarthritis in the very old: prescribe or proscribe?17
Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents17
The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA/RF negative rheumatoid arthritis patients16
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis16
Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis16
Ultrasound for diagnosis and follow-up of chronic axillary vasculitis in patients with long-standing giant cell arteritis15
Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis15
Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibito15
Prognostic factors for 1-year functional outcome, quality of life, care demands, and mortality after surgery in Taiwanese geriatric patients with a hip fracture: a prospective cohort study14
A glimpse into the future of systemic lupus erythematosus14
Cell-based therapies for rheumatoid arthritis: opportunities and challenges14
Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review14
Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?14
Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: a systematic literature review14
Real-world evidence to assess the effectiveness of platelet-rich plasma in the treatment of knee degenerative pathology: a prospective observational study13
Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study13
Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica – a prospective cohort study13
Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis13
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study12
Circulating microRNAs differentiate fast-progressing from slow-progressing and non-progressing knee osteoarthritis in the Osteoarthritis Initiative cohort12
Sjögren syndrome: looking forward to the future11
Associations between glucocorticoids, antiphospholipid antibodies and femur head necrosis in patients with SLE: a directed acyclic graph-based multicentre study11
Gastrointestinal involvement and its association with the risk for nephritis in IgA vasculitis11
Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review11
Back pain treatment: a new perspective11
Age-stratified trends in the progression of spinal radiographic damage in patients with ankylosing spondylitis: a longitudinal study10
Health disparities in rheumatoid arthritis10
Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group10
Bone fragility during the COVID-19 pandemic: the role of macro- and micronutrients10
Association between bone trace elements and osteoporosis in older adults: a cross-sectional study10
Biomarkers for interstitial lung disease and acute-onset diffuse interstitial lung disease in rheumatoid arthritis10
Mesenchymal stromal cell products for intra-articular knee injections for conservative management of osteoarthritis10
Looking ahead: giant-cell arteritis in 10 years time10
A glance into the future of gout10
Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case–control study9
The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities9
Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence9
Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs9
Intra-articular placebo effect in the treatment of knee osteoarthritis: a survey of the current clinical evidence9
Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis9
A glance into the future of diagnosis and treatment of spondyloarthritis9
Soluble biological markers in osteoarthritis9
Epidemiology and risk of invasive fungal infections in systemic lupus erythematosus: a nationwide population-based cohort study9
Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all9
Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis9
Stromal vascular fraction therapy for knee osteoarthritis: a systematic review9
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review9
Interactions of the microbiome with pharmacological and non-pharmacological approaches for the management of ageing-related musculoskeletal diseases9
Inequities in people with gout: a focus on Māori (Indigenous People) of Aotearoa New Zealand9
0.037036180496216